BARDA to announce new BAA for CBRN medical countermeasures

BARDA recently expressed interest in advanced research for the development of medical countermeasures to meet chemical, biological, radiological and nuclear threats to support the HHS Public Health Emergency Medical Countermeasures Enterprise's goals.

BARDA will be looking for the development of vaccines, therapeutics and diagnostic technology to prepare for the possibility of CBRN incidents. PHEMCE etched out its goals in the 2012 PHEMCA Implementation Plan for CBRN Threats, which is available on the Office of the Assistant Secretary for Preparedness & Response website.

The Broad Agency Announcement is intended to gain participation from a number of organizations to further advance CBRN countermeasures. Areas of interest are vaccines, clinical diagnostic tools, chemical threat countermeasures, antitoxins and therapeutics, antimicrobial drugs and radiological/nuclear threat medical countermeasures.

This initiative's goal is the creation of new drug approvals by the U.S. Food and Drug Administration, with the drugs later included in the Strategic National Stockpile and saved in preparation of a CBRN incident.

The official BAA is expected to be released near July 31. It will be an open competition for any biomedical technology organization that can develop CBRN medical countermeasures.